Proteomics of Papillary Thyroid Carcinoma
Study Details
Study Description
Brief Summary
Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
-
Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.
-
Clinical information, examination data: Information is obtained from medical record abstraction.
-
Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary thyroid carcinoma without cervical lymph node metastasis ).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| PTC group 1 papillary thyroid carcinoma patients with cervical lymph node metastasis |
|
| PTC group 2 papillary thyroid carcinoma patients without cervical lymph node metastasis |
|
| Positive control group benign disease |
|
| Negative control group histologically normal |
Outcome Measures
Primary Outcome Measures
- differences in protein expression [6 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Newly diagnosed papillary thyroid carcinoma.
-
Undergo thyroidectomy according to the China thyroid association guidelines forthe Management of thyroid nodule and thyroid cancer.
Exclusion Criteria:
-
Current substance abuse/dependence.
-
Daily tobacco and alcohol use.
-
Whole neck irradiation or surgery.
-
Prior cancer diagnosis or chemotherapy treatment.
-
Active autoimmune disorder.
-
Uncontrolled allergic condition or asthma.
-
Chronic use of oral steroid medication.
-
Hormone therapy (estrogen, progestin compounds).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shan Jin | Hohhot | Inner Mongolia | China | 010050 |
Sponsors and Collaborators
- The Affiliated Hospital of Inner Mongolia Medical University
Investigators
- Study Director: Shan Jin, PhD, Affiliated Hospital of Inner Mongolia Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
- Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006 Aug;45(8):613-26.
- Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi. Review.
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. Review.
- Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G, Foukakis T, Höög A, Auer G, Lehtiö J, Larsson C. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012 Apr;166(4):657-67. doi: 10.1530/EJE-11-0856. Epub 2012 Jan 24.
- AHInnerMongolia-Thyroid-02